



DEPARTMENT OF HEALTH & HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

Public Health Service

Memorandum

OCT 21 1998

Date

From

Senior Regulatory Scientist, Regulatory Branch, Division of Programs & Enforcement Policy (DPEP), Office of Special Nutritionals, HFS-456

3332 '98 OCT 27 P4:54

Subject

75-day Premarket Notification for New Dietary Ingredient

To

Dockets Management Branch, HFA-305


New Dietary Ingredient: Vinpocetine

Firm: Leiner Health Products

Date Received by FDA: October 20, 1998

90-day Date: January 17, 1999

In accordance with the requirements of section 413(a)(2) of the Federal Food, Drug, and Cosmetic Act, the attached 75-day premarket notification for the aforementioned new dietary ingredient should be placed on public display in docket number 95S-0316 after January 17, 1999.


Robert J. Moore, Ph.D.

95S-0316

RPT34



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Washington, DC 20204

OCT 21 1998
3 3 3 3 '98 OCT 27 P4 54

Mr. Michael S. Bradley
Director of Regulatory Affairs
Leiner Health Products
901 E. 233rd Street
Carson, California 90745-6204

Dear Mr. Bradley:

This is to notify you that your submission pursuant to section 413(a)(2) of the Federal Food, Drug, and Cosmetic Act (the Act) dated October 19, 1998, concerning the marketing of a substance that you assert is a new dietary ingredient (i.e., vinpocetine) was received by the Food and Drug Administration (FDA) on October 20, 1998. Your submission will be kept confidential for 90 days from the date of receipt, and after January 17, 1999, your submission will be placed on public display at Dockets Management Branch (Docket No. 95S-0316). Commercial and confidential information in the notification will not be made available to the public.

Please contact us if you have questions concerning this matter.

Sincerely,

A handwritten signature in cursive script that reads "Robert J. Moore".

Robert J. Moore, Ph.D.
Senior Regulatory Scientist
Division of Programs and Enforcement Policy
Office of Special Nutritionals




6/832

901 E. 233rd Street
Carson, California
90745-6204
310/835-8400
Fax 310/835-6615

October 19, 1998

Office of Special Nutritionals (HFS-450)
Center for Food and Safety and Applied Nutrition
Food and Drug Administration
200 C Street SW
Washington DC 20204



Re: 75 – Day Premarket Notification for New Dietary Ingredients

Dear Sir or Madam:

In accordance with the requirements of section 8 of the Dietary Supplement Health and Education Act, Leiner Health Products is notifying the Food and Drug Administration that it will be marketing vinpocetine as a new dietary ingredient.

We take this action with the understanding that Leiner Health Products will not market this product for a period of at least 75 days after the FDA receipt of this notification.

Company Name and Address:

Leiner Health Products
901 E 233rd Street
Carson, CA 90745

Product Name and Chemical Name:

- Vinpocetine
- (3 α , 16 α) Eburnamenine –14-carboxylic acid ethyl ester

Description

The dietary supplement will be in tablet form with a suggested use of a single dose that provides 5 mg of vinpocetine daily.

The labeling will include a warning against the use of this product by pregnant or lactating women.




October 19, 1998
Office of Special Nutritionals (HFS-450)
Center for Food and Safety and Applied Nutrition
Food and Drug Administration
200 C Street SW
Washington DC 20204

Product Safety

Please find attached documentation, which establishes that the new dietary ingredient (vinpocetine) when taken under the suggested use is reasonably expected to be safe.

Respectfully Submitted,



Michael S. Bradley,
Director of Regulatory Affairs

Attached

